Works matching AU Verona, Raluca

Results: 21

Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.

Published in:

2022

By:

DeAngelis, Nikki;
Ferrante, Catherine;
Powers, Gordon;
Sendecki, Jocelyn;
Mattson, Bethany;
Pizutti, Darlene;
Packman, Kathryn;
Wang, Weirong;
Trouba, Kevin;
Nanjunda, Rupesh;
Wheeler, John;
Brittingham, Ray;
Wu, Sheng-Jiun;
Luo, Jinquan;
Lorenzi, Matthew V.;
Verona, Raluca I.

Publication type:

journal article

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

Published in:

Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00966-9

By:

Rodriguez-Otero, Paula;
van de Donk, Niels W. C. J.;
Pillarisetti, Kodandaram;
Cornax, Ingrid;
Vishwamitra, Deeksha;
Gray, Kathleen;
Hilder, Brandi;
Tolbert, Jaszianne;
Renaud, Thomas;
Masterson, Tara;
Heuck, Christoph;
Kane, Colleen;
Verona, Raluca;
Moreau, Philippe;
Bahlis, Nizar;
Chari, Ajai

Publication type:

Article

Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

Published in:

2024

By:

Rodriguez-Otero, Paula;
van de Donk, Niels W. C. J.;
Pillarisetti, Kodandaram;
Cornax, Ingrid;
Vishwamitra, Deeksha;
Gray, Kathleen;
Hilder, Brandi;
Tolbert, Jaszianne;
Renaud, Thomas;
Masterson, Tara;
Heuck, Christoph;
Kane, Colleen;
Verona, Raluca;
Moreau, Philippe;
Bahlis, Nizar;
Chari, Ajai

Publication type:

Correction Notice

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

Published in:

Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00966-9

By:

Rodriguez-Otero, Paula;
van de Donk, Niels W. C. J.;
Pillarisetti, Kodandaram;
Cornax, Ingrid;
Vishwamitra, Deeksha;
Gray, Kathleen;
Hilder, Brandi;
Tolbert, Jaszianne;
Renaud, Thomas;
Masterson, Tara;
Heuck, Christoph;
Kane, Colleen;
Verona, Raluca;
Moreau, Philippe;
Bahlis, Nizar;
Chari, Ajai

Publication type:

Article

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.

Published in:

Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30694-w

By:

Bustoros, Mark;
Anand, Shankara;
Sklavenitis-Pistofidis, Romanos;
Redd, Robert;
Boyle, Eileen M.;
Zhitomirsky, Benny;
Dunford, Andrew J.;
Tai, Yu-Tzu;
Chavda, Selina J.;
Boehner, Cody;
Neuse, Carl Jannes;
Rahmat, Mahshid;
Dutta, Ankit;
Casneuf, Tineke;
Verona, Raluca;
Kastritis, Efstathis;
Trippa, Lorenzo;
Stewart, Chip;
Walker, Brian A.;
Davies, Faith E.

Publication type:

Article

Maintenance of Paternal Methylation and Repression of the Imprinted H19 Gene Requires MBD3.

Published in:

PLoS Genetics, 2007, v. 3, n. 8, p. 1407, doi. 10.1371/journal.pgen.0030137

By:

Reese, Kimberly J.;
Shu Lin;
Verona, Raluca I.;
Schultz, Richard M.;
Bartolomei, Marisa S.

Publication type:

Article

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS.

Published in:

HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000972904.51933.45

By:

Frerichs, Kristine;
Verkleij, Christie;
Mateos, Maria‐Victoria;
Zweegman, Sonja;
Groen, Kaz;
Kuipers, Ilse;
Martin, Tom;
Rodriguez, Cesar;
Nooka, Ajay;
Kruijswijk, Sandy;
Skerget, Sheri;
Doyle, Margaret;
Banerjee, Arnob;
Chastain, Katherine;
Perales‐Puchalt, Alfredo;
Stephenson, Tara;
Uhlar, Clarissa;
Kobos, Rachel;
Verona, Raluca;
van de Donk, Niels W.C.J.

Publication type:

Article

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL‐1.

Published in:

HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970472.64690.4e

By:

Rasche, Leo;
Schinke, Carolina;
Chari, Ajai;
Lipe, Brea C.;
Lavi, Noa;
Rodríguez‐Otero, Paula;
Vishwamitra, Deeksha;
Skerget, Sheri;
Verona, Raluca;
MA, Xuewen;
Khedkar, Sheetal;
Hilder, Brandi;
Masterson, Tara;
Campagna, Michela;
Renaud, Thomas;
Tolbert, Jaszianne;
Heuck, Christoph;
Smit, Damiette;
van de Donk, Niels W.C.J.

Publication type:

Article

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

Published in:

2023

By:

Sidana, Surbhi;
Moreau, Philippe;
Garfall, Alfred;
Bhutani, Manisha;
Oriol, Albert;
Nooka, Ajay;
Martin, Tom;
Rosiñol Dachs, Laura;
Mateos, Maria-Victoria;
Bahlis, Nizar J;
Popat, Rakesh;
Besemer, Britta;
Martinez-Lopez, Joaquín;
Krishnan, Amrita;
Delforge, Michel;
Trancucci, Danielle;
Verona, Raluca;
Stephenson, Tara;
Chastain, Katherine;
van de Donk, Niels W.C.J.

Publication type:

Abstract

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.

Published in:

Targeted Oncology, 2023, v. 18, n. 5, p. 667, doi. 10.1007/s11523-023-00989-z

By:

Miao, Xin;
Wu, Liviawati S.;
Lin, Shun Xin Wang;
Xu, Yan;
Chen, Yang;
Iwaki, Yuki;
Kobos, Rachel;
Stephenson, Tara;
Kemmerer, Kristy;
Uhlar, Clarissa M.;
Banerjee, Arnob;
Goldberg, Jenna D.;
Trancucci, Danielle;
Apte, Amit;
Verona, Raluca;
Pei, Lixia;
Desai, Rachit;
Hickey, Kathleen;
Su, Yaming;
Ouellet, Daniele

Publication type:

Article

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1.

Published in:

Cancer (0008543X), 2025, v. 131, n. 1, p. 1, doi. 10.1002/cncr.35665

By:

Cai, Zhen;
Xia, Zhongjun;
He, Ai‐Li;
Dong, Yu‐Jun;
Wang, Yafei;
Liao, Aijun;
Song, Yang;
Song MM, Juanjuan;
Uhlar, Clarissa;
Chastain, Katherine;
Watkins, Latisha;
Luo, Xinchao;
Huang, Lin;
Niu, Zhuolu;
Quijano Cardé, Natalia A.;
Guo, Yue;
Xu, Hongmei;
Verona, Raluca I.;
Zhou, Longen;
Li, Jingyun

Publication type:

Article

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study.

Published in:

Cancer (0008543X), 2024, v. 130, n. 6, p. 886, doi. 10.1002/cncr.35107

By:

Nooka, Ajay K.;
Rodriguez, Cesar;
Mateos, María Victoria;
Manier, Salomon;
Chastain, Katherine;
Banerjee, Arnob;
Kobos, Rachel;
Qi, Keqin;
Verona, Raluca;
Doyle, Margaret;
Martin, Thomas G.;
van de Donk, Niels W. C. J.

Publication type:

Article

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma.

Published in:

Cancer (0008543X), 2023, v. 129, n. 13, p. 2035, doi. 10.1002/cncr.34756

By:

Martin, Thomas G.;
Mateos, Maria Victoria;
Nooka, Ajay;
Banerjee, Arnob;
Kobos, Rachel;
Pei, Lixia;
Qi, Ming;
Verona, Raluca;
Doyle, Margaret;
Smit, Jennifer;
Sun, Weili;
Trancucci, Danielle;
Uhlar, Clarissa;
van de Donk, Niels W. C. J.;
Rodriguez, Cesar

Publication type:

Article

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer.

Published in:

OncoImmunology, 2021, v. 10, n. 1, p. 1, doi. 10.1080/2162402X.2021.1873607

By:

Martinez, Marina;
Soyeon Kim;
St. Jean, Naomi;
O'Brien, Shaun;
Lurong Lian;
Sun, Jing;
Verona, Raluca I.;
Moon, Edmund

Publication type:

Article

The Transcriptional Status but Not the Imprinting Control Region Determines Allele-Specific Histone Modifications at the Imprinted H19 Locus.

Published in:

Molecular & Cellular Biology, 2008, v. 28, n. 1, p. 6, doi. 10.1128/MCB.01534-07

By:

Verona, Raluca I.;
Thorvaldsen, Joanne L.;
Reese, Kimberly J.;
Bartolomei, Marisa S.

Publication type:

Article

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 1, p. 93, doi. 10.1007/s10637-022-01319-2

By:

Moreno, Victor;
Perets, Ruth;
Peretz-Yablonski, Tamar;
Fourneau, Nele;
Girgis, Suzette;
Guo, Yue;
Hellemans, Peter;
Verona, Raluca;
Pendás, Natalia;
Xia, Qi;
Geva, Ravit;
Calvo, Emiliano

Publication type:

Article

Teclistamab: Mechanism of action, clinical, and translational science.

Published in:

CTS: Clinical & Translational Science, 2024, v. 17, n. 1, p. 1, doi. 10.1111/cts.13717

By:

Guo, Yue;
Quijano Cardé, Natalia A.;
Kang, Lijuan;
Verona, Raluca;
Banerjee, Arnob;
Kobos, Rachel;
Chastain, Katherine;
Uhlar, Clarissa;
Pillarisetti, Kodandaram;
Doyle, Margaret;
Smit, Jennifer;
Haddish‐Berhane, Nahor;
Ouellet, Daniele

Publication type:

Article

TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway.

Published in:

PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0140694

By:

Tomkowicz, Brian;
Walsh, Eileen;
Cotty, Adam;
Verona, Raluca;
Sabins, Nina;
Kaplan, Fred;
Santulli-Marotto, Sandy;
Chin, Chen-Ni;
Mooney, Jill;
Lingham, Russell B.;
Naso, Michael;
McCabe, Timothy

Publication type:

Article

Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 7, p. 1117, doi. 10.1002/psp4.13144

By:

Willemin, Marie‐Emilie;
Wang Lin, Shun Xin;
De Zwart, Loeckie;
Wu, Liviawati S.;
Miao, Xin;
Verona, Raluca;
Banerjee, Arnob;
Liu, Baolian;
Kobos, Rachel;
Qi, Ming;
Ouellet, Daniele;
Goldberg, Jenna D.;
Girgis, Suzette

Publication type:

Article

P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S39, doi. 10.1016/S2152-2650(21)02135-2

By:

Girgis, Suzette;
Shun Xin Wang Lin;
Pillarisetti, Kodandaram;
Verona, Raluca;
Vieyra, Diego;
Casneuf, Tineke;
Fink, Damien;
Xin Miao;
Yang Chen;
Stephenson, Tara;
Banerjee, Arnob;
Hilder, Brandi;
Russell, Jeffery;
Smit, Jennifer;
Goldberg, Jenna

Publication type:

Article

OAB-025: Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)×CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study.

Published in:

Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S16, doi. 10.1016/S2152-2650(21)02099-1

By:

Donk, Niels W.C.J. van de;
Krishnan, Amrita;
Oriol, A;
Berdeja, Jesus G.;
Rodríguez-Otero, Paula;
Askari, Elham;
Mateos, María-Victoria;
Minnema, Monique C.;
Costa, Luciano;
Verona, Raluca;
Girgis, Suzette;
Prior, Thomas;
Hilder, Brandi;
Russell, Jeffery;
Goldberg, Jenna;
Chari, Ajai

Publication type:

Article